Senseonics’ Earnings Call Highlights Growth Amid Challenges

Senseonics Holdings Inc. ((SENS)) has held its Q3 earnings call. Read on for the main highlights of the call.

Senseonics Holdings Inc. recently held its earnings call, revealing a generally positive sentiment driven by significant revenue growth and successful marketing strategies. The company reported record new patient starts and highlighted its direct-to-consumer approach as a key factor in its positive outlook. However, ongoing financial losses and anticipated inventory challenges during the transition from Ascensia were noted as areas of concern.

Exceptional Third Quarter Performance

Senseonics reported a remarkable 90% year-over-year revenue growth in Q3 2025. This growth was significantly bolstered by new patient shipments, which saw a 160% increase compared to the previous year. The company’s performance in this quarter marks a notable achievement in its financial trajectory.

Successful Direct-to-Consumer Strategy

The company’s investments in direct-to-consumer marketing have paid off, leading to a 300% increase in patient leads year-over-year and an 85% sequential increase. Impressively, 60% of new patients were acquired through DTC advertising, underscoring the effectiveness of this strategy.

Record New Patient Starts

September was a milestone month for Senseonics, recording the highest number of new patient starts in its history. This contributed to the most successful quarter ever, with new insertions increasing nearly 150% year-over-year.

Gross Margin Improvements

The company reported an improvement in gross profit margins, rising from 25% at the end of 2024 to over 40% in 2025. Looking ahead, Senseonics projects gross margins to reach 50% in 2026 and approximately 70% at scale.

European Expansion Plans

Senseonics is preparing for the European launch of Eversense 365, with the CE mark application expected to be approved by the end of 2025. The launch is planned for the first half of 2026, utilizing the company’s own sales force.

Partnership with Sequel

The company is working on integrating Eversense 365 with Sequel’s twiist insulin delivery system. This partnership is anticipated to be a significant growth driver in 2026.

Net Loss Reduction but Continuing Losses

Despite a reduction in net loss to $19.5 million in Q3 2025 from $24 million in Q3 2024, Senseonics continues to face financial challenges. The ongoing losses highlight the need for continued financial management.

Inventory and Transition Challenges

The transition from Ascensia is expected to present some onetime inventory challenges, which may affect revenue recognition in 2026. This transition is a critical area for the company to manage effectively.

Delayed European Launch

The transition of European operations from Ascensia is taking longer than expected, delaying the launch of Eversense 365 in Europe to the first half of 2026. This delay is a significant consideration for the company’s international expansion plans.

Forward-Looking Guidance

Senseonics provided forward-looking guidance that highlights its growth trajectory. The company anticipates continued revenue growth, driven by increased patient shipments and successful marketing strategies. Gross profit margins are expected to improve to 50% in 2026, with a target of 70% at scale. The European launch of Eversense 365 is planned for the first half of 2026, pending CE mark approval.

In conclusion, Senseonics’ earnings call reflected a positive sentiment with impressive growth metrics and strategic marketing successes. While the company faces ongoing financial challenges and inventory issues during its transition from Ascensia, its forward-looking guidance and strategic partnerships position it well for future growth. Investors and stakeholders will be keen to see how these plans unfold in the coming months.